[ ]
|
Preliminary Proxy Statement
|
[ ]
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
[X]
|
Definitive Proxy Statement
|
[ ]
|
Definitive Additional Materials
|
[ ]
|
Soliciting Material Pursuant §240.14a-12
|
OCULUS INNOVATIVE SCIENCES, INC.
|
(Name of Registrant as Specified in its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
[X]
|
No fee required.
|
||
[ ]
|
Fee computed based on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
||
1)
|
Title of each class of securities to which transaction applies:
|
||
2)
|
Aggregate number of securities to which transaction applies:
|
||
3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
||
4)
|
Proposed maximum aggregate value of transaction:
|
||
5)
|
Total fee paid:
|
||
[ ]
|
Fee paid previously with preliminary materials.
|
||
[ ]
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
||
1)
|
Amount Previously Paid:
|
||
2)
|
Form, Schedule or Registration Statement No.:
|
||
3)
|
Filing Party:
|
||
4)
|
Date Filed:
|
||
1.
|
To elect two Class III directors, nominated by our Board of Directors, to serve until the 2014 Annual Meeting or until their successors are duly elected and qualified;
|
2.
|
To approve the adoption of the 2011 Stock Incentive Plan;
|
3.
|
To ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2012; and
|
4.
|
To transact such other business as may properly come before the 2011 Annual Meeting and any adjournments or postponements thereof.
|
General Information Concerning Voting and Solicitation
|
5 | |
Proposal No. 1 Election of a Class of Directors
|
7 | |
Information as to our Board of Directors and Nominees
|
7 | |
Director Compensation
|
13 | |
Executive Officers
|
14 | |
Executive Compensation
|
15 | |
Security Ownership of Certain Beneficial Owners and Management
|
20 | |
Certain Relationships and Related Transactions
|
22 | |
Section 16(a) Beneficial Ownership Reporting Compliance
|
22 | |
Report of the Audit Committee
|
23 | |
Proposal No. 2 Approval of the Company’s 2011 Stock Incentive Plan
|
24 | |
Proposal No. 3 Ratification of the Appointment of Independent Registered Public Accounting Firm
|
26 | |
Shareholder Proposals for the 2012 Annual Meeting
|
27 | |
Other Matters
|
27 |
|
·
|
The election of two Class III directors, nominated by the Board of Directors, to serve until the 2014 Annual Meeting or until their successors are duly elected and qualified;
|
|
·
|
The approval of the Company’s 2011 Stock Incentive Plan;
|
|
·
|
The ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2012.
|
•
|
“FOR”
Proposal No. 1 to elect each of the nominated directors;
|
|
•
|
“FOR”
Proposal No. 2 to approve the adoption of the Company’s 2011 Stock Incentive Plan; and
|
|
•
|
“FOR”
Proposal No. 3 to ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2012.
|
•
|
By Mail
— Sign and date each proxy card you receive and return it in the prepaid envelope. Sign your name exactly as it appears on the proxy. If you return your signed proxy but do not indicate your voting preferences, we will vote your shares ”FOR” all of our director nominees; “FOR” the adoption of our 2011 Stock Incentive Plan; and “FOR” the ratification of the selection of Marcum LLP as our independent registered public accounting firm for fiscal year 2011. Stockholders of record may vote by mail or in person at the 2011 Annual Meeting.
|
|
•
|
By Telephone or the Internet
— If you are a beneficial owner, you will receive instructions from the holder of record that you must follow in order for your shares to be voted. Telephone and Internet voting will be offered to stockholders owning shares through most banks and brokers. Follow the instructions located on your voting instruction form. Please be aware that if you vote over the Internet, you may incur costs such as telephone and Internet access charges for which you will be responsible. If you vote by telephone or via the Internet, you do not need to return your voting instruction form to your bank or broker.
|
|
•
|
In Person at the 2011 Annual Meeting
— Shares held in your name as the stockholder of record may be voted at the 2011 Annual Meeting. Shares held beneficially in street name may be voted in person only if you obtain a legal proxy from the broker, bank or nominee that holds your shares giving you the right to vote the shares.
Even if you plan to attend the 2011 Annual Meeting, we recommend that you also submit your proxy or voting instructions or vote by telephone or the Internet so that your vote will be counted if you later decide not to attend the meeting.
|
Name
|
Age
|
Position With the Company
|
Director Since
|
|||||||
Hojabr Alimi (4)
|
50
|
Chairman of the Board, Chief Executive Officer and Class I Director
|
1999
|
|||||||
Jim Schutz (4)
|
48
|
Chief Operating Officer, General Counsel, and Class I Director
|
2004
|
|||||||
Gregg Alton (1)(3)
|
45
|
Class II Director
|
2008
|
|||||||
Jay Birnbaum (1)
|
66
|
Class II Director
|
2007
|
|||||||
Richard Conley (1)(2)(3)(4)
|
61
|
Class III Director
|
1999
|
|||||||
Gregory French (2)(3)
|
50
|
Class III Director
|
2000
|
(1)
|
Member of the Audit Committee
|
|
(2)
|
Member of the Compensation Committee
|
|
(3)
(4)
|
Member of the Nominating and Corporate Governance Committee
Member of the Acquisition and Strategy Committee
|
Name
|
Biography
|
Qualifications
|
Hojabr Alimi
|
Mr. Alimi co-founded our Company with his spouse in 1999. He has served as our Chief Executive Officer, President and director since 1999 and was appointed as Chairman of our Board of Directors in June 2006.
Mr. Alimi received a B.A. in biology from Sonoma State University.
|
·
Depth of operating, scientific, and senior management experience in our industry both at Oculus and prior to joining Oculus, including as:
o
Oculus’ Chief Executive Officer and President
o
Corporate Microbiologist at Arterial Vascular Engineering
|
Jim Schutz
|
Mr. Schutz has served most recently as our Chief Operating Officer and our General Counsel and in various capacities as an Executive Officer since August 2003, and as a director since May 2004. From August 2001 to August 2003, Mr. Schutz served as General Counsel at Jomed (formerly EndoSonic Corp.), an international medical device company. From 1999 to July 2001, Mr. Schutz served as in-house counsel at Urban Media Communications Corporation, an Internet/telecom company based in Palo Alto, California.
Mr. Schutz received a B.A. in economics from the University of California, San Diego and a J.D. from the University of San Francisco School of Law.
|
·
Depth of compliance, transactional, strategic, senior management experience in our industry, both at Oculus and prior to Oculus, including as:
o
Oculus’ Chief Operating Officer, General Counsel, and Corporate Secretary
o
General Counsel at Jomed
|
Gregg H. Alton
|
Since 1999, Mr. Alton has served as Senior Vice President and Secretary of Gilead Sciences Inc., a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies.
Mr. Alton is a board member and treasurer of the AIDS Healthcare Foundation, and a board member of BayBio, a life sciences industry organization in the San Francisco Bay Area.
He received his B.A. in Legal Studies from the University of California at Berkeley and his J.D. from Stanford University.
|
·
Depth of compliance, transactional, merger and acquisition, corporate partnership, strategic, and senior management experience in the biopharmaceutical industry, including as:
o
Senior Vice President and Secretary of Gilead
o
Attorney at Cooley Godward, LLP
·
Depth of experience serving on boards of directors (and certain of their key positions) of non-profit organizations related to healthcare and of organizations in the life sciences industry
|
Number of Members:
|
3
|
|
Current Members:
|
Richard Conley (Chair and Audit Committee Financial Expert)
Gregg H. Alton
Jay Birnbaum
|
|
Number of Meetings in fiscal year 2011:
|
8
|
|
Functions:
|
The Audit Committee provides assistance to the Board of Directors in fulfilling its oversight responsibilities relating to the Company’s financial statements, system of internal control over financial reporting, and auditing, accounting and financial reporting processes. Other specific duties and responsibilities of the Audit Committee are to appoint, compensate, evaluate and, when appropriate, replace the Company’s independent registered public accounting firm; review and pre-approve audit and permissible non-audit services; review the scope of the annual audit; monitor the independent registered public accounting firm’s relationship with the Company; and meet with the independent registered public accounting firm and management to discuss and review the Company’s financial statements, internal control over financial reporting, and auditing, accounting and financial reporting processes.
|
Number of Members:
|
2
|
|
Current Members:
|
Gregory French (Chair)
Richard Conley
|
|
Number of Meetings in fiscal year 2011:
|
6
|
|
Functions:
|
The Compensation Committee’s primary functions are to assist the Board of Directors in meeting its responsibilities in regard to oversight and determination of executive compensation and to review and make recommendations with respect to major compensation plans, policies and programs of the Company. Other specific duties and responsibilities of the Compensation Committee are to review and approve goals and objectives relevant to the recommendations for approval by the independent members of the Board of Directors regarding compensation of our Chief Executive Officer and other executive officers, establish and approve compensation levels for our Chief Executive Officer and other executive officers, and to administer our stock plans and other equity-based compensation plans.
|
Number of Members:
|
3
|
|
Current Members:
|
Gregg Alton (Chair)
Gregory French
Richard Conley
|
|
Number of Meetings in fiscal year 2011:
|
4
|
|
Functions:
|
The Nominating and Corporate Governance Committee’s primary functions are to identify qualified individuals to become members of the Board of Directors, determine the composition of the Board and its Committees, and monitor a process to assess Board effectiveness. Other specific duties and responsibilities of the Nominating and Corporate Governance Committee are to recommend nominees to fill vacancies on the Board of Directors, review and make recommendations to the Board of Directors with respect to candidates for director proposed by stockholders, and review on an annual basis the functioning and effectiveness of the Board and its Committees.
|
Number of Members:
|
3
|
|
Current Members:
|
Richard Conley (Chair)
Hojabr Alimi
Jim Schutz
|
|
Number of Meetings in fiscal year 2011:
|
6
|
|
Functions:
|
The Acquisition and Strategy Committee’s primary functions are to review the Company’s strategic direction and, when and if they arise, review potential mergers, acquisitions or dispositions of material assets or a material portion of any business and report its conclusions to the Board of Directors, as appropriate. The Acquisition and Strategy Committee will also meet with executive officers of the Company as appropriate to review potential issues.
|
Name of Director
|
Fees earned or paid in cash ($)
|
Option awards ($) (1)
|
All other compensation ($)
|
Total ($)
|
Gregg Alton
|
35,000
|
18,734 (2)
|
0
|
53,734
|
Jay Birnbaum
|
30,000
|
18,734 (3)
|
0
|
48,734
|
Richard Conley
|
39,000
|
18,734 (4)
|
0
|
57,734
|
Gregory French
|
32,000
|
18,734 (5)
|
0
|
50,734
|
(1)
|
Represents the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating the amounts in this column may be found in Note 14 to our audited consolidated financial statements for the year ended March 31, 2011 included in our Annual Report on Form 10-K filed with the SEC on June 3, 2011. These amounts do not represent the actual amounts paid to or realized by the directors during the fiscal year ended March 31, 2011.
|
(2)
|
On December 20, 2010, we granted Mr. Alton options to purchase 15,000 shares of our common stock. These options vest in equal monthly installments over the period of one year and expire on December 20, 2020.
|
(3)
|
On December 20, 2010, we granted Mr. Birnbaum options to purchase 15,000 shares of our common stock. These options vest in equal monthly installments over the period of one year and expire on December 20, 2020.
|
(4)
|
On December 20, 2010, we granted Mr. Conley options to purchase 15,000 shares of our common stock. These options vest in equal monthly installments over the period of one year and expire on December 20, 2020.
|
(5)
|
On December 20, 2010, we granted Mr. French options to purchase 15,000 shares of our common stock. These options vest in equal monthly installments over the period of one year and expire on December 20, 2020.
|
Name
|
Number of Shares
|
Gregg Alton
|
105,000
|
Jay Birnbaum
|
170,000
|
Richard Conley
|
334,570
|
Gregory French
|
313,906
|
In Current
|
||||||||||
Name
|
Age
|
Capacities in Which Served
|
Position Since
|
|||||||
Hojabr Alimi
|
50
|
Chief Executive Officer, President and Chairman
|
1999
|
|||||||
Robert Miller
|
69
|
Chief Financial Officer
|
2004
|
|||||||
Jim Schutz
|
48
|
Chief Operating Officer, General Counsel and Director
|
2006
|
|||||||
Name and Principal
Position
|
Year Ended
March 31,
|
Salary ($)
|
Bonus ($)
|
Option
awards ($) (1)
|
All other compensation ($)
|
Total ($)
|
Hojabr Alimi
Chief Executive
Officer, President and
Chairman (Principal
Executive Officer)
|
2011
|
375,000
|
432,000 (2)
|
0
|
40,460 (3)
|
847,460
|
2010
|
376,442
|
0
|
215,370
|
15,018 (4)
|
606,830
|
|
Robert Miller
Chief Financial Officer
(Principal Financial
and Accounting
Officer)
|
2011
|
250,000
|
0
|
213,259
|
9,906 (5)
|
473,165
|
2010
|
250,962
|
0
|
269,213
|
9,932 (6)
|
530,107
|
|
Jim Schutz
Chief Operating
Officer, General
Counsel, and Director
|
2011
|
300,000
|
0
|
246,496
|
16,814 (7)
|
563,309
|
2010
|
257,500
|
23,000
|
261,375
|
14,130 (8)
|
556,005
|
(1)
|
Represents the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating the amounts in this column may be found in Note 14 to our audited consolidated financial statements for the year ended March 31, 2011 included in our Annual Report on Form 10-K filed with the SEC on June 3, 2011. The amounts in this column do not represent the actual amounts paid to or realized by the executives during the fiscal year ended March 31, 2011.
|
(2)
|
Mr. Alimi’s bonus compensation consisted of: (a) a one-time cash bonus of $166,000 on November 3, 2010; (b) a one-time cash bonus of $83,000 on August 5, 2010; (c) a one-time cash bonus of $83,000 on June 29, 2010; and (d) a one-time cash bonus of $100,000 on April 2, 2010.
|
(3)
|
The 2011 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $4,844; (b) matching IRA contribution in the amount of $8,223; and (c) payment of $2,291 to cover premium for life insurance policy for the benefit of Mr. Alimi, and (d) payment of $25,102 related to personal financial planning services.
|
(4)
|
The 2010 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $2,952; (b) matching IRA contribution in the amount of $5,451; (c) payment of $2,748 to cover premium for life insurance policy for the benefit of Mr. Alimi; and (d) payment of $3,867 related to personal financial planning services.
|
(5)
|
The 2011 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $1,680; (b) matching IRA contribution in the amount of $7,676; and (c) payment of $550 to cover premium for life insurance policy for the benefit of Mr. Miller.
|
(6)
|
The 2010 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $2,345; (b) matching IRA contribution in the amount of $7,035; and (c) payment of $552 to cover premium for life insurance policy for the benefit of Mr. Miller.
|
(7)
|
The 2011 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $6,004; (b) matching IRA contribution in the amount of $9,405; and (c) payment of $1,405 to cover premium for life insurance policy for the benefit of Mr. Schutz.
|
(8)
|
The 2010 perquisites and personal benefits include (a) personal use of a Company automobile in the amount of $5,278; (b) matching IRA contribution in the amount of $7,457; and (c) payment of $1,395 to cover premium for life insurance policy for the benefit of Mr. Schutz.
|
•
|
a lump severance payment equal to 18 times, in the case of Mr. Miller and Mr. Schutz, 24 times, in the case of Mr. Alimi, the average monthly base salary paid to the named executive officer over the preceding 12 months (or for the term of the named executive officer’s employment if less than 12 months);
|
•
|
automatic vesting of all unvested options and other equity awards;
|
|
•
|
the extension of exercisability of all options and other equity awards to at least 12 months following the date the named executive officer terminates employment or, if earlier, until the option expires;
|
|
•
|
up to one year (the lesser of one year following the date of termination or until such named executive officer becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and
|
|
•
|
a full gross up of any excise taxes payable by the officer under Section 4999 of the Internal Revenue Code because of the foregoing payments and acceleration (including the reimbursement of any additional federal, state and local taxes payable as a result of the gross up).
|
Continuation of
|
Value of
|
|||||||||||||||
Health and
|
Unvested
|
|||||||||||||||
Salary
|
Welfare
|
Equity
|
Excise Tax and
|
|||||||||||||
Name
|
Continuation
|
Benefits (1)
|
Awards (2)
|
Gross-up (3)
|
||||||||||||
Hojabr Alimi
|
$
|
750,000
|
$
|
19,812
|
$
|
91,677
|
$
|
402,746
|
||||||||
Robert Miller
|
375,000
|
47,388
|
59,423
|
225,247
|
||||||||||||
Jim Schutz
|
450,000
|
19,812
|
56,579
|
246,088
|
(1)
|
Amount assumes our cost of providing health and welfare benefits for twelve months.
|
(2)
|
The values reflect the immediate vesting of all outstanding options and other equity awards as of termination, based on a March 31, 2011 closing stock price of $2.01 and exclude amounts for accelerated options that have an exercise price higher than such closing stock price.
|
(3)
|
The assumptions used to calculate excise and associated taxes are as follows:
|
•
|
termination occurs on March 31, 2011; and
|
|
•
|
the named executive officer was assumed to be subject to the maximum Federal and California income and other payroll taxes, aggregating to an effective tax rate of 46.75%.
|
|
·
|
If some or all of the Target Milestones are met, then the bonus may equal up to 58% of individual base salary.
|
|
·
|
If some or all of the Stretch Milestone are met, then the bonus may equal up to 68% of individual base salary.
|
|
·
|
If some or all of the Target Milestones are met, then the bonus may equal up to 48% of individual base salary.
|
|
·
|
If some or all of the Stretch Milestones are met, then the bonus may equal up to 64% of individual base salary.
|
|
·
|
If some or all of the Target Milestones are met, then the bonus may equal up to 52% of individual base salary.
|
|
·
|
If some or all of the Stretch Milestones are met, then the bonus may equal up to 66% of individual base salary.
|
|
·
|
If some or all of the Target Milestones are met, then the bonus may equal up to 58% of individual base salary.
|
|
·
|
If some or all of the Stretch Milestone are met, then the bonus may equal up to 68% of individual base salary.
|
|
·
|
If some or all of the Target Milestones are met, then the bonus may equal up to 48% of individual base salary.
|
|
·
|
If some or all of the Stretch Milestones are met, then the bonus may equal up to 64% of individual base salary.
|
|
·
|
On June 16, 2011, pursuant to the FY 2011 Bonus Plan, the Compensation Committee of the Board of Directors awarded Hojabr Alimi, our Chairman of the Board of Directors and Chief Executive Officer, $240,000 in cash for meeting his stated Target and Stretch Milestones.
|
|
·
|
On June 16, 2011, pursuant to the FY 2011 Bonus Plan, the Compensation Committee of the Board of Directors awarded Robert Miller, our Chief Financial Officer, 175,000 options at an exercise price of $1.60 in lieu of cash. 83,333 shares of the award vested immediately. The remaining 91,667 shares of the award will vest 1/36th per month over a three-year vesting period from the date of grant.
|
|
·
|
On June 16, 2011, pursuant to the FY 2011 Bonus Plan, the Compensation Committee of the Board of Directors awarded Jim Schutz, our Chief Operating Officer, 50,000 options at an exercise price of $1.60, which are exercisable immediately, in lieu of cash.
|
Option Awards
|
||||
Name
|
Number of securities
underlying unexercised
options (#)
exercisable
|
Number of securities underlying unexercised options (#)
unexercisable
|
Option exercise price ($)
|
Option expiration date
|
Hojabr Alimi (1)
|
||||
89,062
|
60,938
|
1.97
|
06/07/2020
|
|
194,001
|
96,999
|
1.09
|
03/10/2019
|
|
12,500
|
-
|
10.16
|
10/01/2015
|
|
5,000
|
-
|
3.00
|
08/07/2013
|
|
19,570
|
-
|
3.00
|
07/10/2013
|
|
Robert Miller (2)
|
||||
83,333
|
91,667
|
1.60
|
06/16/2021
|
|
12,500
|
-
|
2.01
|
03/31/2021
|
|
116,406
|
71,094
|
1.97
|
06/07/2020
|
|
123,001
|
61,499
|
1.09
|
03/10/2019
|
|
6,250
|
-
|
10.16
|
10/01/2015
|
|
34,633
|
-
|
3.00
|
07/10/2014
|
|
39,181
|
-
|
3.00
|
07/10/2014
|
|
Jim Schutz (3)
|
||||
50,000
|
-
|
1.60
|
06/16/2021
|
|
56,250
|
81,250
|
2.01
|
03/31/2021
|
|
62,500
|
-
|
1.97
|
06/07/2020
|
|
125,000
|
-
|
1.91
|
02/10/2020
|
|
123,001
|
61,499
|
1.09
|
03/10/2019
|
|
74,999
|
25,001
|
7.27
|
06/15/2017
|
|
6,250
|
-
|
10.16
|
10/01/2015
|
|
50,000
|
-
|
3.00
|
07/10/2014
|
|
43,750
|
-
|
3.00
|
07/10/2014
|
|
50,000
|
-
|
3.00
|
09/23/2013
|
(1)
|
Options with an expiration date of June 7, 2020 vest 50% immediately upon grant with the remaining 50% vesting in monthly in equal amounts over the 48 months following the grant date. Options with an expiration date of March 10, 2019 vest over a three-year period, becoming exercisable as to 16.7% of the shares on the six month anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 30 months. Options with an expiration date of October 1, 2015 vest over a five-year period, becoming exercisable as to 20% of the shares on the first anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 48 months. Options with an expiration date of July 10, 2013 and August 7, 2013 vest over a five-year period, becoming exercisable as to 20% of the shares on each anniversary of the grant date.
|
(2)
|
Options with an expiration date of June 16, 2021 vest immediately as to 83,333 shares, with the remaining 91,667 shares vesting 1/36 per month over a three year period from the date of grant. Options with an expiration date of March 31, 2021 vest immediately upon grant. Options with an expiration date of June 7, 2020 vest immediately as to 100,000 shares, with the remaining 987,500 shares vesting monthly in equal amounts over the 48 months following the grant date. Options with an expiration date of March 10, 2019 vest over a three-year period, becoming exercisable as to 16.7% of the shares on the six month anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 30 months. Options with an expiration date of October 1, 2015 vest over a five-year period, becoming exercisable as to 20% of the shares on the first anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 48 months. The 34,633 options with an expiration date of July 10, 2014 were fully vested at grant and were immediately exercisable. The 39,181 options with an expiration date of July 10, 2014 vested quarterly beginning September 30, 2004 and ending September 30, 2005.
|
(3)
|
Options with an expiration date of June 16, 2021 vest immediately upon grant. Options with an expiration date of March 31, 2021 vest immediately as to 56,250 shares, with the remaining 81,250 shares vesting 1/36 per month over a three year period. Options with an expiration date of June 7, 2020 vest immediately upon grant. Options with an expiration date of February 10, 2020 vest as to 16.7% of the shares on the six month anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 30 months. Options with an expiration date of March 10, 2019 vest over a three-year period, becoming exercisable as to 16.7% of the shares on the six month anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 30 months. Options with an expiration date of June 15, 2017 and October 1, 2015 vest over a five-year period, becoming exercisable as to 20% of the shares on the first anniversary of the grant date with the remaining shares vesting monthly thereafter over the following 48 months. Options with an expiration date of July 10, 2014 and September 23, 2013 vest over a five-year period, becoming exercisable as to 20% of the shares on each anniversary of the grant date.
|
Name and address of beneficial owner
|
Amount of beneficial ownership
|
Percent of Shares Beneficially Owned*
|
Seamus Burlingame
c/o Burlingame Industries, Inc.
3546 N. Riverside Avenue
Rialto, CA 92377
|
1,580,504 (1)
|
5.9%
|
(1)
|
We relied on Mr. Seamus Burlingame for this information. Mr. Burlingame’s beneficial ownership is comprised of 1,580,504 shares of our common stock. Mr. Burlingame holds common stock purchase warrants originally exercisable into 2,333,333 shares of common stock, in the aggregate. However, the aggregate number of shares of common stock into which such warrants are exercisable, and which Mr. Burlingame has the right to acquire beneficial ownership, is limited to the number of shares of common stock that, together with all other shares of common stock beneficially owned by Mr. Burlingame does not exceed 4.99% of the total outstanding shares of our common stock. Accordingly, such warrants are not currently exercisable into common stock until the actual shares of common stock held by Mr. Burlingame is less than 4.99% of the total outstanding shares of our common stock. Therefore, the common stock purchase warrants owned by Mr. Burlingame are not included in the calculation of beneficial ownership. Mr. Burlingame has sole voting and dispositive power over the 1,580,504 shares of common stock.
|
Amount of beneficial ownership
|
Percent of Shares
Beneficially Owned (2)
|
||||
Name and address of beneficial owner (1)
|
Nature of beneficial ownership
|
Shares
Owned
|
Shares – Rights to Acquire (3)
|
Total
Number
|
|
Hojabr Alimi (4)
|
President, Chief Executive Officer and Chairman of the Board of Directors
|
1,011,250
|
378,007
|
1,389,257
|
5.1%
|
Robert Miller (5)
|
Chief Financial Officer
|
73,000
|
462,082
|
535,082
|
2.0%
|
Jim Schutz (6)
|
Chief Operating Officer, General Counsel, and a member of our Board of Directors
|
53,500
|
692,117
|
745,617
|
2.7%
|
Gregg Alton (7)
|
Member of our Board of Directors
|
0
|
101,111
|
101,111
|
*
|
Jay Birnbaum (8)
|
Member of our Board of Directors
|
0
|
166,111
|
166,111
|
*
|
Richard Conley (9)
|
Member of our Board of Directors
|
122,650
|
270,681
|
393,331
|
1.5%
|
Gregory French (10)
|
Member of our Board of Directors
|
52,760
|
250,017
|
302,777
|
1.1%
|
All directors and executive officers as a group (7 persons)
|
1,313,160
|
2,320,126
|
3,633,286
|
12.5%
|
(1)
|
Unless otherwise stated, the address of each beneficial owner listed on the table is c/o Oculus Innovative Sciences, Inc., 1129 N. McDowell Blvd., Petaluma, California 94954.
|
(2)
|
On July 15, 2011, we had 26,793,348 shares of common shares issued and outstanding.
|
(3)
|
Represents shares subject to outstanding stock options and warrants currently exercisable or exercisable, or currently vested or that will vest, within 60 days of July 15, 2011.
|
(4)
|
Mr. Alimi is our President, Chief Executive Officer and Chairman of the Board of Directors. Mr. Alimi beneficially owns 1,011,250 shares of common stock and 378,007 shares of common stock issuable within 60 days of July 15, 2011.
|
(5)
|
Mr. Miller is our Chief Financial Officer. Mr. Miller beneficially owns 73,000 shares of common stock and 462,082 shares of common stock issuable within 60 days of July 15, 2011.
|
(6)
|
Mr. Schutz is our Chief Operating Officer, General Counsel, and a member of our Board of Directors. Mr. Schutz beneficially owns 53,500 shares of common stock and 692,117 shares of common stock issuable within 60 days of July 15, 2011.
|
(7)
|
Mr. Alton is a member of our Board of Directors. Mr. Alton beneficially owns 101,111 shares of common stock issuable within 60 days of July 15, 2011.
|
(8)
|
Dr. Birnbaum is a member of our Board of Directors. Dr. Birnbaum beneficially owns 166,111 shares of common stock issuable within 60 days of July 15, 2011.
|
(9)
|
Mr. Conley is a member of our Board of Directors. Mr. Conley beneficially owns 122,650 shares of common stock and 270,681 shares of common stock issuable within 60 days of July 15, 2011.
|
(10)
|
Mr. French is a member of our Board of Directors. Mr. French beneficially owns 52,760 shares of common stock and 250,017 shares of common stock issuable within 60 days of July 15, 2011.
|
2011
|
2010
|
|||||||
Audit Fees
|
$ | 197,000 | $ | 217,000 | ||||
Audit-Related Fees
|
31,000 | 68,000 | ||||||
Tax Fees
|
- | - | ||||||
All Other Fees
|
- | |||||||
Total
|
$ | 231,000 | $ | 285,000 |
SECTION 1. ESTABLISHMENT AND PURPOSE
|
1
|
SECTION 2. DEFINITIONS
|
1
|
SECTION 3. ADMINISTRATION
|
3
|
SECTION 4. ELIGIBILITY
|
4
|
SECTION 5. STOCK SUBJECT TO PLAN
|
5
|
SECTION 6. RESTRICTED SHARES
|
5
|
SECTION 7. TERMS AND CONDITIONS OF OPTIONS
|
6
|
SECTION 8. PAYMENT FOR SHARES
|
7
|
SECTION 9. STOCK APPRECIATION RIGHTS
|
7
|
SECTION 10. STOCK UNITS
|
8
|
SECTION 11. ADJUSTMENT OF SHARES
|
9
|
SECTION 12. DEFERRAL OF AWARDS
|
9
|
SECTION 13. AWARDS UNDER OTHER PLANS
|
10
|
SECTION 14. PAYMENT OF DIRECTOR’S FEES IN SECURITIES
|
10
|
SECTION 15. LEGAL AND REGULATORY REQUIREMENTS
|
10
|
SECTION 16. WITHHOLDING TAXES
|
10
|
SECTION 17. OTHER PROVISIONS APPLICABLE TO AWARDS
|
11
|
SECTION 18. NO EMPLOYMENT RIGHTS
|
11
|
SECTION 19. DURATION AND AMENDMENTS
|
11
|
SECTION 20. EXECUTION
|
11
|
OCULUS INNOVATIVE SCIENCES, INC.
|
|||
|
By:
|
/s/ Robert Miller | |
Name: | Robert Miller | ||
Title: | Chief Financial Officer | ||